Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Geneva, Switzerland and Boston, MA - February 23, 2018 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that it will release the top line results from the IMPLANT2 clinical trial of its oxytocin receptor antagonist, Nolasiban, which is being developed for improving pregnancy rate following in vitro fertilization (IVF/ICSI) procedures, on the morning of Monday February 26, 2018. ObsEva management will host an investment community conference call at 8 a.m. Eastern Time, 2 p.m. Central European Time, on February 26, 2018 to discuss these results.
Investors may participate by dialing +1(844) 419-1772 for U.S. callers and +1(213) 660-0921 for international callers, and referring to conference ID 9784807. The webcast can be accessed under the "Investors" section of ObsEva's website www.obseva.com
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.
###
Media Contact:
Liz Bryan
Spectrum Science
[email protected]
202-955-6222 x2526
CEO Office contact:
Shauna Dillon
[email protected]
+41 22 552 1550
Investor Contact:
Mario Corso
Senior Director, Investor Relations
[email protected]
781-366-5726
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/875bf795-85d0-4113-b453-10a7f908f49c
